This study focuses on Cutaneous Lupus Erythematosus, a skin condition that causes rashes and lesions, which may occur with or without Systemic Lupus Erythematosus, an autoimmune disease affecting multiple organs. The research evaluates a new medication called VENT-03, which is taken as tablets by mouth.

The purpose of this research is to determine how well VENT-03 works in reducing the severity of skin symptoms in adults with active cutaneous lupus. During the study, participants will receive either VENT-03 tablets or placebo tablets that look identical but contain no active medication. After the initial phase where neither participants nor doctors know who receives which treatment, the study continues with an open-label extension where all participants receive the active medication.

The study will measure how the skin symptoms change over time, particularly focusing on the improvement in skin lesions. Throughout the study, participants will undergo various health assessments to monitor their response to treatment and ensure their safety. The medication’s levels in the blood will also be measured to understand how the body processes it.